Skip to main content
Premium Trial:

Request an Annual Quote

Harbinger Health: Dymeka Harrison, Mathew Sargent, and Gisela Paulsen 

Harbinger Health has appointment Dymeka Harrison as its chief commercial officer, Mathew Sargent as its chief business officer, and Gisela Paulsen as its chief operating officer. Harrison boasts over 20 years of experience in the diagnostics industry, most recently as chief commercial officer at Foundation Medicine. Prior to that, she was head of strategic marketing at Abbott Laboratories' rapid diagnostics division. She earned an MBA from Georgia State University and a Bachelor of Science at North Carolina A&T State University. Sargent comes to Harbinger after serving as VP of commercial oncology at Hologic following its acquisition of Biotheranostics, where he served as chief commercial officer. He previously held roles including first VP of of oncology sales at Caris Life Sciences. Sargent holds an MBA from Pepperdine University, an MS from the University of Buffalo, and a BS from Cornell University. Paulsen has held executive roles at several diagnostics companies including Oncocyte, Genomic Health, and Genentech/Roche across commercial, program management, quality and regulatory, and other administrative functions. She graduated from Uppsala University in Sweden with a MS in pharmaceutics and drug delivery and a BS in pharmacy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.